MedPath

Tagged News

Inavolisib Combination Significantly Improves Survival in PIK3CA-Mutant Advanced Breast Cancer

Precision Medicine
  • The phase 3 INAVO120 trial demonstrated that adding inavolisib to palbociclib and fulvestrant significantly improved overall survival in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.
  • This triple combination therapy represents a potential new treatment standard for this specific patient population with endocrine-resistant disease.
  • The findings highlight the importance of targeting PIK3CA mutations in hormone receptor-positive breast cancer patients who have developed resistance to endocrine therapy.

First Immunotherapy Success in Prostate Cancer Shows Promise for DNA Repair-Deficient Tumors

Precision Medicine
  • A landmark clinical trial demonstrates that pembrolizumab immunotherapy provides survival benefits for a subset of men with advanced, otherwise untreatable prostate cancer.
  • Of 258 men treated with pembrolizumab, 38% remained alive after one year and 11% continued treatment without disease progression.
  • Men with DNA repair gene mutations in their tumors showed higher response rates, suggesting genetic testing could identify optimal candidates for immunotherapy.
  • Researchers are planning a new trial specifically targeting prostate cancer patients with DNA repair mutations to validate this precision medicine approach.

Landmark TAILORx Trial Shows 70% of Early-Stage Breast Cancer Patients Can Safely Skip Chemotherapy

Precision MedicineOncology
• The TAILORx trial, involving over 10,000 women, demonstrates that approximately 70% of patients with hormone-receptor positive, HER2-negative early breast cancer can safely avoid chemotherapy when guided by genetic testing. • Women over 50 with Oncotype DX recurrence scores of 0-25 showed no significant survival benefit from adding chemotherapy to hormone therapy alone. • The findings could spare an estimated 65,000 women annually in the US from chemotherapy's toxic side effects while maintaining excellent long-term outcomes. • This precision medicine approach represents the largest breast cancer trial to date and marks a paradigm shift toward personalized treatment strategies.

D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial

OncologyPrecision MedicineTargeted Therapy
  • A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
  • The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
  • Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy